THE EFFECT OF TOPICAL MEDICATION CONTAININGBENZALKONIUMCHLORIDE ON OCULAR SURFACE DISEASE INGLAUCOMA PATIENTS
DOI:
https://doi.org/10.61841/msezt378Keywords:
benzalkonium chloride, glaucoma, ocular surface disease, Schirmer I test, corneal stainingAbstract
Background, The main cause of the emergence of dry eye and ocular surface disease (OSD) is strongly suspected due to the preservative component of topical medication in the form of benzalkonium chloride (BAK). Various complaints such as uncomfortable, teary, redness, burning and foreign object sensation, glare, often blinking and intermittent blurred vision has-been reported as part of OSD. Objective: The study aimed to investigate the effect of topical medication containing BAK on ocular OSD in glaucoma patients Method: Subject who has been using topical antiglaucomatous medication containing BAK and artificial tears were examined for tear film break up time (TBUT), S I test and corneal staining. Sucject were allowed to close the eyes, then positioned in front of the slit-lamp biomicroscope. A regression test was used to analyze the correlation between each variable. Result: TBUT and S I test were decreased, and corneal staining score was increased; furthermore, BAK is significantly correlated with all of the examination result by using regression test. The effect of the amount and duration of BAK used is significantly correlated with TBUT (p = 0.004). The effect of the amount and duration of BAK used insignificantly correlated with S I test (p = 0.043). This study also has R value as 0.901; >0.05, showing the amount and duration of BAK used strongly affect TBUT, S I test and corneal staining score. Conclusion: BAK has strong correlation on the event of ocular surface disease.
Downloads
References
[1] Amparo, F., Schaumberg, D., and Dana, R. (2015), ‘Comparison of Two Questionnaires for Dry Eye Symptom Assessment: The Ocular Surface Disease Index and the Symptom Assessment in Dry Eye’, Ophthalmology, 122(7), pp. 1498–503.
[2] Artini, W. et al. (2018), ‘Comparison of the goblet cells’ density and the quality of tears in treatment with sodium hyaluronate 0.1% benzalkonium chloride preservative-free eye drops for patients with glaucoma and dry-eye syndrome: A double-blind randomized clinical trial’, J of Physics, 51, pp. 10–16.
[3] Fidalia, Bahar, E., and Rizki, S. (2019), ‘Correlation between the Use of Topical Antiglaucoma Containing Preservative Benzalkonium Chloride with the Degree of Dry Eye Syndrome in Mohammad Hoesin Hospital Palembang’, J of Res in Med and Dental Sci, 7, p. 4.
[4] Georgiev, G. et al. (2011), ‘Surface chemistry study of the interactions of benzalkonium chloride with films of Meibom, corneal cell lipids, and whole tears’, Invest Ophthalmol Vis Sci., 52(7), pp. 4645–54.
[5] Halasz, K. et al. (2019), ‘Micro/Nanoparticle Delivery Systems for Ocular Diseases’, Assay and Drug Development Technologies, 17(4), pp. 152–166.
[6] Januleviciene, I., Derkac, I., and Grybauskiene, L. (2012), ‘No Effects of preservative-freetafluprost on tear film osmolarity, tolerability, and intraocular pressure in previously treated patients with open-angle glaucoma’, Clin Ophthalmol, 6, pp. 103–109.
[7] Kaštelan, S. et al. (2013), ‘How ocular surface disease impacts the glaucoma treatment outcome’, Biomed Res Int, 2013, pp. 1–7.
[8] Leung, E., Medeiros, F., and Weinreb, R. (2008), ‘Prevalence of ocular surface disease in glaucoma patients’, J Glaucoma, 17, pp. 350–355.
[9] Marques, D. et al. (2015), ‘Lacrimal osmolarity and ocular surface in an experimental model of dry eye caused by toxicity’, Bras Ophthal, 12(2), pp. 57–59.
[10] Mathews, P. et al. (2013), ‘Evaluation of ocular surface disease in patients with glaucoma’, Ophthalmology, 120(11), pp. 2241-8.
[11] Moss, S., Klein, R., and Klein, B. (2000), ‘Prevalence of and risk factors for dry eye syndrome’, ArchOphthalmol, 118, pp. 1264–1268.
[12] Rosin, L., and Bell, N. (2013), ‘Preservative toxicity in glaucoma medication: clinical evaluation of benzalkonium chloride-free 0.5% timolol eye drops’, Clin Ophtalmol, 7, pp. 2131–35.
[13] Shaarawy, T. et al. (2014) Glaucoma. 2nd edn. Elsevier Saunders.
[14] Walimbe, T. et al. (2016), ‘Effect of benzalkonium chloride-free latanoprost ophthalmic solution on ocular surface in patients with glaucoma’, Clin Ophthalmol, 10(215–17).
[15] Zhang, X. et al. (2019), ‘Ocular surface disease and glaucoma medication: a clinical approach’, Eye Contact Lens, 45(1), pp. 11-18.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 AUTHOR
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
